Literature DB >> 12911275

Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C.

Sabina Mahmood1, Gotaro Yamada, Gouichi Niiyama, Miwa Kawanaka, Kazumi Togawa, Miho Sho, Toshio Ito, Takayo Sasagawa, Misako Okita, Hajime Nakamura, Junji Yodoi.   

Abstract

OBJECTIVES: Oxidative stress induces cellular responses such as cell death, gene activation and cell proliferation, in the liver. Vitamin E (Vit. E) has been found to protect the liver against oxidative stress in animal experiments. Thioredoxin (TRX) is a stress inducible, multifunctional protein, secreted during oxidative stress. This study evaluated effects of Vit. E on serum TRX and aminotransferase levels in hepatitis C virus (HCV) patients, partly non-responsive to initial interferon (IFN), with higher than average level of serum alanine aminotransferase (ALT) after receiving anti-inflammatory drug treatment.
METHODS: Seventeen HCV patients (male = 3; female = 14) of age 62 +/- 7.65 years receiving anti-inflammatory drug therapy, at least 6 months prior to Vit. E administration, were given d-alpha-tocopherol 500 mg/day, orally, for a period of 3 months. ALT, aspartate aminotransferase (AST), TRX and Vit. E were measured at 0, 1, 2 and 3 months and 1 month after end of treatment. As controls, the same patients biochemical data, 3 months from the start of therapy were used. Patients were divided into three categories: total patients "T", low ALT group "L" (ALT < 70 IU/l) and high ALT group "H" (ALT > 70 IU/l), respectively.
RESULTS: The ALT level was lowered, significantly in group H, in the 1st, 2nd, 3rd and 1-month post therapy, compared to the initial value. But group L showed little or no change in ALT. Post Vit. E therapy, in groups T and H, the TRX level was elevated but remained below initial levels, whereas in group L, TRX level remained significantly lower than the pretreatment value. Groups T and L, showed significant reduction (p < 0.05) in serum TRX levels in the 2nd and 3rd month. Group H showed a tendency towards TRX reduction, but not significantly. Serum Vit. E levels increased significantly (p < 0.0001) from the 1st to 3rd month in all three T, H and L groups.
CONCLUSION: Oxidative stress induced liver damage is reduced by Vit. E in patients with viral hepatitis C, particularly those with initial ALT levels > 70 IU/l. Vit. E treatment causes reduction of oxidative stress markers as TRX and ALT in sera. Therefore, Vit. E can act as a supportive therapy to combat liver damage caused by oxidative stress, in such patients with continuously high levels of ALT even after anti-viral and anti-inflammatory drug therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911275     DOI: 10.1080/1071576031000102141

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  14 in total

1.  Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.

Authors:  M K Baum; S Sales; D T Jayaweera; S Lai; G Bradwin; C Rafie; J B Page; A Campa
Journal:  HIV Med       Date:  2011-02       Impact factor: 3.180

Review 2.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

Authors:  Koji Miyanishi; Toshifumi Hoki; Shingo Tanaka; Junji Kato
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

Review 5.  Antioxidants as therapeutic agents for liver disease.

Authors:  Ashwani K Singal; Sarat C Jampana; Steven A Weinman
Journal:  Liver Int       Date:  2011-07-29       Impact factor: 5.828

Review 6.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

7.  Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C.

Authors:  Swati Joshi-Barve; Kiranmayi Amancherla; Madhuvanti Patil; Aruni Bhatnagar; Stephanie Mathews; Leila Gobejishvili; Matthew Cave; Craig McClain; Shirish Barve
Journal:  Free Radic Biol Med       Date:  2009-04-01       Impact factor: 7.376

8.  Hepatitis C virus to hepatocellular carcinoma.

Authors:  Shah Jahan; Usman A Ashfaq; Muhammad Qasim; Saba Khaliq; Muhammad Javed Saleem; Nadeem Afzal
Journal:  Infect Agent Cancer       Date:  2012-01-30       Impact factor: 2.965

Review 9.  Nutritional therapy and infectious diseases: a two-edged sword.

Authors:  Haig Donabedian
Journal:  Nutr J       Date:  2006-09-04       Impact factor: 3.271

10.  An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy.

Authors:  Sabina Mahmood; Kazumi Togawa; Miwa Kawanaka; Gouichi Niiyama; Gotaro Yamada
Journal:  Cancer Inform       Date:  2008-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.